ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.
31. März 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra...
MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19
08. März 2021 07:00 ET
|
Mateon Therapeutics, Inc.
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01. März 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™
01. Februar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
04. November 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud...
MATEON ADVISOR DR. SUHAS KSHIRSAGAR WILL PRESENT AT DELHI UNIVERSITY ON ARTISHIELD™ FOR IMPROVING SYMPTOMS FOR COVID-19
23. Oktober 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Dr. Kshirsagar will speak on ARTIShield™ at Delhi University on Oct 28, 2020 in his talk titled “Ayurveda concepts of Pandemic and Immunity”Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product...
MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.
19. Oktober 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Republica Argentina – Poder...
MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
12. Oktober 2020 08:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.
13. Juli 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
10. Juni 2020 08:00 ET
|
Mateon Therapeutics
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...